Dutch firm argenx, J&J affiliate to collaborate on cancer therapy

Netherlands-based biopharmaceutical company argenx SE said it signed a deal with Cilag GmbH International, an affiliate of Johnson & Johnson's Janssen Pharmaceutical Companies unit, to develop its Cusatuzumab drug in certain types of cancer.

from Reuters: Health News https://ift.tt/2EaA4OI
via IFTTT